Table 1 Baseline characteristics of status epilepticus (SE) patients treated with intravenous phenytoin or intravenous sodium valproate as the first-line treatment

Age;(years)

40 (16–85)

42 (16–76)

0.852

Male gender (%)

17 (45.95)

10 (58.82)

0.379

No preexisting condition, N (%)

5 (13.51)

3 (17.65)

0.696

History of epilepsy (%)

6 (16.22)

7 (41.18)

0.084

Antiepileptic drug withdrawal (%)

4 (10.81)

5 (29.41)

0.121

Admitted to internal medicine ward (%)

14 (37.84)

6 (35.29)

1.000

Generalized tonic clonic seizure type (%)

37 (100)

16 (94.12)

0.315

Weight (kgs)*

55.5 (40–75)

50 (39–97.5)

0.343

Time to start treatment (minutes)

5 (5–90)

10 (5–35)

0.127

Independent status prior to SE, N (%)

28 (75.68)

17 (100)

0.177

Laboratory findings

Hematocrit, g/dL*

31 (15.6-45.7)

36.5 (26–49.4)

0.273

Total white blood cells, cells/mm³*

11610 (4100–29700)

8965 (1100–14500)

0.168

Blood sugar, mg/dL*

127 (37–568)

131 (73–251)

0.926

Serum creatinine, md/dL*

1 (0.5-6.1)

0.9 (0.5-7)

0.445

Serum calcium, md/dL*

8.4 (5.3-10.2)

8.2 (0.9-10.7)

0.976

Serum albumin, g/dL*

3.3 (1.2-7.4)

4.0 (2.2-5.1)

0.072

ALT, U/L*

30 (5–375)

18 (4–165)

0.242

AST, U/L*

56 (11–473)

25.5 (0.3-2.2)

0.115

Creatinine kinase, U/L*

276 (54–1500)

174.5 (44–500)

0.396

Abnormal CT brain findings*

17 (58.62)

7 (53.85)

1.000

Electroencephalogram, N*

9 (24.32)

5 (29.42)

0.745